Key Takeaways
- Strong H1, on track for targets: Revenue grew 15.1% YoY in Q3, with PAT up 21.8% YoY, keeping the company on track for its 15% revenue and 20% PAT/EPS growth commitment.
- Volume-led chronic play is working: Chronic and semi-chronic segments contribute ~70% of revenue, driving volume growth that consistently outpaces the IPM by over 1.5x.
- Inorganic levers are active and integrating: The Bayer Zydus brand acquisition and Ferring in-licensing deals are progressing, with infertility launches planned this year, adding new therapy legs to the growth story.
- International ambition is taking shape: A "think hormone, think CORONA" export strategy is being built on backward integration via La Chandra Pharma, targeting higher single-digit revenue contribution in a couple of years.
- What to watch next quarter: The commercial kick-start of the new hormonal plant, the first product launches from the acquired infertility portfolio, and any quantification of the margin range for FY27.
Financial Performance
- Top-line momentum: Q3 FY26 revenue of INR 361.1 crores grew 15.1% YoY, while H1 FY26 revenue of INR 707.7 crores grew 17% YoY, with India contributing over 96% of the business in both periods.
- Profitability improved: Q3 EBITDA grew 17.4% YoY to INR 78.5 crores with margins expanding 40 bps to 21.7%; H1 EBITDA grew 27.4% YoY to INR 148.3 crores with margins up 170 bps to 20.9%.
- Bottom-line delivery: Q3 PAT grew 21.8% YoY to INR 52.3 crores; H1 PAT grew 35.1% YoY to INR 98.5 crores, outpacing revenue growth and aligning with the 20% PAT/EPS growth target.
- Capital efficiency: Annualized ROE stood at 31.1% and ROCE at 49.7% for H1, supported by strong OCF to EBITDA conversion of 76.5% and tight net working capital days of 23.
- Balance sheet strength: The company operates as a net cash surplus entity with an A+ credit rating, providing capacity for organic and inorganic reinvestment.
- Seasonal stability: With over 70% of the business in chronic and semi-chronic therapies, seasonality is muted; the H1/H2 revenue split is roughly 50-50, with Q3 typically contributing 25-27% of annual revenue due to the festive season.
Nirav Mehta: "we are on track to deliver 15% CAGR, 15% revenue growth and 20% PAT or EPS growth for next three to four years."
India Business & Brand Strategy
- Outpacing the market: CORONA consistently grows at more than 1.5x the IPM and was ranked the number one fastest growing pharmaceutical company among the top 30 as per MAT September 2025 PharmaTrac data.
- Chronic-focused portfolio: The company concentrates on chronic and semi-chronic segments, which contribute approximately 70% of total revenues and provide a stable, volume-driven growth trajectory.
- Science-led brand building: Products are launched with a differentiated, science-based positioning, converting molecules into brands through consistency and quality, exemplified by the B29 brand for neuro diabetic neuropathy management.
- PCPM productivity ramp: Current per capita per month productivity of ~4 lakhs is lower than some chronic-heavy peers because newer reps (0-3 years) contribute only 2-2.5 lakhs, while mature reps (6-9 years) contribute 8 lakhs, indicating a natural productivity ramp with tenure.
- Market structure tailwind: Approximately 79% of the 8.5% IPM growth is captured by the top 50 companies, with the remainder spread across 1,300-1,400 smaller players, favoring scaled, chronic-focused entities like CORONA.
- Geographic and specialist shift: The India strategy is shifting focus from rural to semi-urban, urban, and metro markets, targeting the ~70,000 recently added specialist and super specialist seats in the country.
Nirav Mehta: "Brand gives a flavor, a quality adherence and the confidence in the set customer's mind."
Inorganic Growth & Portfolio Expansion
- Bayer Zydus acquisition: In July 2025, CORONA acquired seven brand trademarks from Bayer Zydus Pharma, entering the INR 1,500+ crore anti-platelet market (Noklot, Noklot CV) and adding infertility (Fostine, Menodac, Ovidac) and women's healthcare products.
- Ferring in-licensing: CORONA became one of only three Indian companies to in-license brands from Swiss multinational Ferring Pharmaceuticals, adding products in women's healthcare and urology therapies.
- Infertility launch imminent: Products from the Bayer Zydus acquisition are under development and will launch in the core infertility therapy this year, marking the first unlock of six-seven new therapies under development.
- New therapy pipeline: Beyond infertility, the company is working on spine, rheumatoid, CNS, dermatology, and gastrointestinal therapies, each to be unlocked at the right time, with infertility as the first mover this year.
- M&A philosophy: Future inorganic and in-licensing opportunities will be evaluated based on strategic fitment and what can be done with the product range, with no preference between MNC or Indian assets; the culture and character of the brand is the deciding factor.
Nirav Mehta: "The important is what sort of culture we are acquiring out of the brand, what sort of character we are acquiring from the brand."
International Business & Manufacturing Build-out
- "Think hormone, think CORONA": The international strategy centers on developing a complex generic female hormonal product portfolio, leveraging backward and forward integration from the investment in La Chandra Pharma Lab.
- La Chandra integration: La Chandra operates an EU GMP and WHO GMP certified hormonal API manufacturing facility in Gujarat and supplies hormone API to CORONA under a right of first refusal arrangement, securing the supply chain for the export push.
- Global reach planned: The hormonal portfolio will target worldwide markets excluding the US and Japan initially, covering Europe, UK, Australia, New Zealand, Brazil, Mexico, Asia, CIS, and Russia.
- New plant progress: The hormonal formulation plant building is ready with a Schedule M license obtained; commercial production is expected to kick-start by end of Q2 or early Q3 of FY27, with WHO approval targeted by Q4 of FY27.
- Phased contribution: The new plant will initially serve India-based products for the first few quarters, with international business using female hormones to follow, and a top-line contribution expected in FY28.
- International revenue ambition: Management is hopeful of achieving a contribution of around 8-9% (higher single-digit) from international business in a couple of years.
Nirav Mehta: "The theme for international market remain - think hormone, think CORONA. It's absolutely a niche in this segment."
Operations, ESG & People
- Capacity expansion: A new capacity of around 40 crore tablets and capsules was commissioned at the Gujarat facility in December 2025, supporting volume-led domestic growth.
- ESG recognition: The World Bank Group awarded CORONA the EDGE Advanced certificate for energy and water saving measures, and the company is investing in a 4.25 megawatt solar park spread over 11.9 acres to save on electricity costs.
- Zero liquid discharge: An effluent treatment plant at the Bhayla facility has been set up to achieve zero liquid discharge, underscoring a commitment to environmental compliance.
- Anti-counterfeiting: The company is working with QR code technology on product strips to combat counterfeiting.
- MR expansion planned: The field force is expected to expand by 5-7% year-on-year, a necessity for launching new super specialty therapies like infertility, spine, and rheumatoid.
- R&D spend: R&D expenditure will remain below 2% of revenue as the top line grows, with a modest expansion of the R&D team planned.
Nirav Mehta: "Yes, you heard right, zero liquid discharge."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Deliver 15% CAGR and 15% annual revenue growth | Next 3-4 years |
| PAT/EPS growth | Deliver 20% PAT or EPS growth year-on-year | Next 4 years (plan till FY29) |
| MR expansion | Expand medical representative numbers by 5-7% YoY | Annual, ongoing |
| New plant commercial start | Commercial production kick-start at hormonal plant | End of Q2 or early Q3 FY27 |
| New plant WHO approval | Obtain WHO approval for hormonal plant | Q4 FY27 |
| International contribution | Achieve higher single-digit (~8-9%) revenue contribution from international business | In a couple of years |
| Infertility portfolio launch | Launch acquired Bayer Zydus infertility products | This year (FY26/FY27) |
| R&D spend ceiling | Maintain R&D spend at less than 2% of revenue | Ongoing |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹361.1 cr, +15.1% YoY; India business 96.5% of total |
| H1 FY26 revenue | ₹707.7 cr, +17% YoY; India business 96.4% of total |
| EBITDA | ₹78.5 cr, +17.4% YoY |
| EBITDA margin | 21.7%, improved ~40 bps YoY |
| H1 FY26 EBITDA margin | 20.9%, improved ~170 bps YoY |
| Profit after tax | ₹52.3 cr, +21.8% YoY |
| H1 FY26 profit after tax | ₹98.5 cr, +35.1% YoY |
| Annualized ROE (H1 FY26) | 31.1% |
| Annualized ROCE (H1 FY26) | 49.7% |
| OCF to EBITDA (H1 FY26) | 76.5% |
| Net working capital days | 23 days |
| Chronic and semi-chronic revenue share | ~70% of total revenues |
| PCPM (domestic business) | ~₹3.9 lakhs, ranging from ₹2-2.5 lakhs (0-3 yr reps) to ₹8 lakhs (6-9 yr reps) |
| Medical representatives | ~2,600 plus, planned expansion at 5-7% YoY |
| International business contribution | ~3.5% of total revenue |